Autolus Therapeutics plc ADR
Autolus Therapeutics plc ADR (AUTL) Covered Calls
Autolus Therapeutics plc ADR trades in the Biotechnology industry with an IV Rank of 99.60%, high versus the past year. AUTL's highest covered call setup is the $2.50 strike expiring Jun 17, 2027, sorted by theoretical annualized return. It's 129.36% out of the money with 212 days to expiration, a 133.94% return until expiration, and a 230.61% theoretical annualized return. Across the setups shown, annualized returns run from 230.61% to 230.61% at strikes between $2.50 and $2.50, with 212 days to expiration, as of Nov 17, 2026.
Read more
Running AUTL covered calls helps you generate income from Autolus Therapeutics plc ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AUTL covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If AUTL stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AUTL covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AUTL covered call is worth writing.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
| 2027-06-17 | 212 | 2.50 | 129.36 | 0.05 | 0.20 | 146.00 | 133.94 | 230.61 | -4.59 | +0.31 | 264 | 0.15 |
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank99.60% High
- Market cap (M$)282
- 52 weeks high-58.91%
- 52 weeks low-0.93%
- Analyst recommendationStrong Buy
1.00 - Target price$8.10
664.15% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-0.96
- EPS growth next 5 years25.74%
As of Nov 18, 2026